EVENTS, PRESENTATIONS & PUBLICATIONS
Pipeline
Building a broad portfolio of respiratory therapeutics
Patient Resources
Helping to understand and improve respiratory care
May 2025
Developing innovative therapies for the treatment of respiratory diseases
We aim to improve health and wellbeing for those affected by chronic respiratory diseases.
Latest News
VRNA Presentation May 2025
2.0MB
Ohtuvayre® FDA Approval Presentation June 2024
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
Effective October 7th, 2025, Verona Pharma Plc and it subsidiaries1 are subsidiaries of Merck & Co., Inc. (Rahway, New Jersey USA)
1 Subsidiaries include Verona Pharma, Inc. (US) and Verona Pharma Ireland Limited (Ireland).
